Latest Advances in Lung Cancer Research

AstraZeneca and Daiichi Sankyo’s Enhertu scored an accelerated FDA approval in patients with HER2-mutant NSCLC.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.

New NSCLC targeted therapy guidelines have been published. They are updates to the 2017 systemic therapy recommendations.

Amivantamab Approved for EGFR Exon 20–Positive NSCLC. FDA approval marks this as a first treatment for patients with EGFR exon 20 insertion.

Sotorasib Approved for KRAS G12C NSCLC. First FDA approved treatment for KRAS-positive non small cell lung cancer.

An interview with Dr. Gregory Masters discussing the latest guidelines treating non-small cell lung cancer (NSCLC) with gene mutations.

Tepotinib approved for MET+ NSCLC treatment. Specifically, approval for metastatic NSCLC with MET exon 14 skipping alterations.

Tagrisso as adjuvant therapy for non-small cell lung cancer approved by the FDA for patients who have had tumor resection.

Amgen has filed its trailblazer KRAS inhibiting drug treatment with the FDA for a group of lung cancer patients with an aggressive form of the disease.